Press Releases AptarGroup, Inc.

Equities

ATR

US0383361039

Non-Paper Containers & Packaging

Market Closed - Nyse Other stock markets 16:00:02 2026-04-13 EDT			5-day change	1st Jan Change
132.11 ^USD	+0.46%		+4.84%	+8.32%

04-08	Aptar Partners With Enable Injections for enFuse Digital Service	MT
04-08	Aptar digital health partners with Enable Injections for Enfuse® companion digital solution	RE

Press Releases

04-09	Aptar Digital Health Partners with Enable Injections for enFuse(R) Companion Digital Solution	AQ
04-08	Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution	BU
03-20	Aptar's Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA-051 Nasal Spray	AQ
03-19	Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray	BU
03-17	Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year	BU
03-02	AptarGroup : Bank of America 2026 Injectable Drug Packaging Virtual Field Trip	PU
02-25	AptarGroup : Bank of America 2026 Global Agriculture and Materials Conference	PU
02-18	Aptar to Participate in Upcoming Investor Conferences	BU
02-06	AptarGroup : Fourth Quarter 2025 Historical Financials	PU
02-05	AptarGroup : Fourth Quarter 2025 Press Release	PU
02-05	AptarGroup : Fourth Quarter 2025 Presentation	PU
02-05	AptarGroup: Q4 Earnings Snapshot	AQ
02-05	Aptar Reports Fourth Quarter and Annual 2025 Results	BU
01-22	Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details	BU
01-22	Aptar Again Recognized with Prestigious 'A' Score on the CDP Climate Change Assessment	AQ
01-21	Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment	BU
01-14	Aptar's Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate	AQ
01-13	Aptar's Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink	AQ
01-07	Aptar Announces 2026 Quarterly Conference Call Dates	BU
01-06	Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring	BU
01-05	Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026	BU
12-18	Aptar's Bidose Nasal System Delivers CARDAMYST (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)	AQ
12-17	Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)	BU
12-04	Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year	BU
11-25	AptarGroup : Task Force on Climate-Related Financial Disclosure (TCFD)	PU